BRAIN Biotech AG reports solid 9M numbers despite ongoing high R&D investments and more challenging economic conditions

30 August 2023, Zwingenberg (Germany)  - BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, today published solid 9M results of FY2022/2023. Despite an increasingly challenging economic environment and ongoing high investments especially in its Akribion Genomics genome editing platform, BRAIN Biotech stays on track towards its stated fiscal year targets.